Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: David Szekeres

Premium

Regulus Therapeutics has named David Szekeres as its chief business officer and general counsel.

In the new role, he will be responsible for business development, strategic planning, and legal efforts, Regulus said.

Most recently, Szekeres served as deputy general counsel and chief mergers and acquisition counsel for Life Technologies.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.